Skip to main content
Erschienen in: International Journal of Hematology 5/2011

01.11.2011 | Review Article

The challenges of adherence and persistence with iron chelation therapy

verfasst von: John B. Porter, Michael Evangeli, Amal El-Beshlawy

Erschienen in: International Journal of Hematology | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Due to advances in medical sciences, many chronic diseases that formerly resulted in early death can now be effectively managed with long-term treatment regimens. Patients with potentially fatal anemias, for example, can be treated with ongoing blood transfusions and iron chelation therapy. Ensuring adherence and persistence is challenging, as the benefits of therapy are not perceived immediately. Poor adherence severely compromises the effectiveness of treatment and, therefore, improving compliance in terms of quality of life and health economics is critical. Although adherence to chelation therapy is generally poor, the availability of oral iron chelators may help to improve patient compliance. For chronic conditions such as thalassemia major, even when oral chelation therapy is available, support by an integrated team including a clinical psychologist and nurse specialist working with the treatment center is recommended to achieve optimal results.
Literatur
1.
Zurück zum Zitat Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–7.PubMedCrossRef Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–7.PubMedCrossRef
3.
Zurück zum Zitat Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18:277–87.PubMedCrossRef Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18:277–87.PubMedCrossRef
4.
Zurück zum Zitat Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17–24.PubMedCrossRef Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17–24.PubMedCrossRef
6.
Zurück zum Zitat Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade®, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873–80.PubMed Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade®, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873–80.PubMed
8.
Zurück zum Zitat al Refaie FN, Sheppard LN, Nortey P, et al. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol. 1995;89:403–8.PubMedCrossRef al Refaie FN, Sheppard LN, Nortey P, et al. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol. 1995;89:403–8.PubMedCrossRef
9.
Zurück zum Zitat Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia. Eur J Haematol. 2009;82:454–7.PubMedCrossRef Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia. Eur J Haematol. 2009;82:454–7.PubMedCrossRef
10.
Zurück zum Zitat Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567–73.PubMedCrossRef Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567–73.PubMedCrossRef
11.
Zurück zum Zitat Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26–36.PubMedCrossRef Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26–36.PubMedCrossRef
12.
Zurück zum Zitat Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355:2051–2.PubMedCrossRef Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355:2051–2.PubMedCrossRef
13.
Zurück zum Zitat Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–93.PubMed Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–93.PubMed
14.
Zurück zum Zitat Matsui D, Hermann C, Klein J, et al. Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J Clin Pharmacol. 1994;34:944–9.PubMed Matsui D, Hermann C, Klein J, et al. Critical comparison of novel and existing methods of compliance assessment during a clinical trial of an oral iron chelator. J Clin Pharmacol. 1994;34:944–9.PubMed
15.
16.
Zurück zum Zitat Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47:1919–29.PubMedCrossRef Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47:1919–29.PubMedCrossRef
17.
Zurück zum Zitat Delea TE, Sofrygin O, Baladi J-F, Thomas SK, Phatak P, Coates TD. Costs and consequences of inadequate compliance with deferoxamine therapy in patients with transfusion-dependent thalassemia. Presented at International Society for Pharmaceutical and Outcomes Research (ISPOR), May 20–24, Philadelphia, PA 2006. Delea TE, Sofrygin O, Baladi J-F, Thomas SK, Phatak P, Coates TD. Costs and consequences of inadequate compliance with deferoxamine therapy in patients with transfusion-dependent thalassemia. Presented at International Society for Pharmaceutical and Outcomes Research (ISPOR), May 20–24, Philadelphia, PA 2006.
18.
Zurück zum Zitat Cappellini MD. Overcoming the challenge of patient compliance with iron chelation therapy. Semin Hematol. 2005;42:S19–21.PubMedCrossRef Cappellini MD. Overcoming the challenge of patient compliance with iron chelation therapy. Semin Hematol. 2005;42:S19–21.PubMedCrossRef
19.
Zurück zum Zitat Windebank KP, Spinetta JJ. Do as I say or die: compliance in adolescents with cancer. Pediatr Blood Cancer. 2008;50:1099–100.PubMedCrossRef Windebank KP, Spinetta JJ. Do as I say or die: compliance in adolescents with cancer. Pediatr Blood Cancer. 2008;50:1099–100.PubMedCrossRef
20.
Zurück zum Zitat Maggio A, D’Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis. 2002;28:196–208.PubMedCrossRef Maggio A, D’Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis. 2002;28:196–208.PubMedCrossRef
21.
Zurück zum Zitat Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738–44.PubMedCrossRef Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738–44.PubMedCrossRef
22.
Zurück zum Zitat Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88:489–96.PubMed Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88:489–96.PubMed
23.
Zurück zum Zitat Fischer R, Longo F, Nielsen P, et al. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with β-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol. 2003;121:938–48.PubMedCrossRef Fischer R, Longo F, Nielsen P, et al. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with β-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol. 2003;121:938–48.PubMedCrossRef
24.
Zurück zum Zitat Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol. 2006;85:315–9.PubMedCrossRef Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol. 2006;85:315–9.PubMedCrossRef
25.
Zurück zum Zitat El-Beshlawy A, Manz C, Naja M, et al. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Ann Hematol. 2008;87:545–50.PubMedCrossRef El-Beshlawy A, Manz C, Naja M, et al. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Ann Hematol. 2008;87:545–50.PubMedCrossRef
26.
Zurück zum Zitat Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care. 2000;9:2–6.PubMed Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care. 2000;9:2–6.PubMed
27.
Zurück zum Zitat Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J. 2002;95:68–71.PubMed Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J. 2002;95:68–71.PubMed
28.
Zurück zum Zitat Trachtenberg F, Vichinsky E, Haines D, et al. Iron chelation adherence to deferoxamine and deferasirox in thalassemia. Am J Hematol. 2011;86:433–6.PubMedCrossRef Trachtenberg F, Vichinsky E, Haines D, et al. Iron chelation adherence to deferoxamine and deferasirox in thalassemia. Am J Hematol. 2011;86:433–6.PubMedCrossRef
29.
Zurück zum Zitat Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther. 2007;29:909–17.PubMedCrossRef Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther. 2007;29:909–17.PubMedCrossRef
30.
Zurück zum Zitat Vichinsky E, Pakbaz Z, Onyekwere O, et al. Patient-reported outcomes of deferasirox (Exjade®, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis: substudy of a randomized open-label Phase II trial. Acta Haematol. 2008;119:133–41.PubMedCrossRef Vichinsky E, Pakbaz Z, Onyekwere O, et al. Patient-reported outcomes of deferasirox (Exjade®, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis: substudy of a randomized open-label Phase II trial. Acta Haematol. 2008;119:133–41.PubMedCrossRef
31.
Zurück zum Zitat Garbowski M, Eleftheriou P, Pennell D et al. Impact of compliance, ferritin and LIC on long-term trends in myocardial T2* with deferasirox. Blood. 2008;112(11):abst 116. Garbowski M, Eleftheriou P, Pennell D et al. Impact of compliance, ferritin and LIC on long-term trends in myocardial T2* with deferasirox. Blood. 2008;112(11):abst 116.
32.
Zurück zum Zitat Evangeli M, Mughal K, Porter JB. Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review. Hemoglobin. 2010;34:305–21.PubMedCrossRef Evangeli M, Mughal K, Porter JB. Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review. Hemoglobin. 2010;34:305–21.PubMedCrossRef
33.
Zurück zum Zitat Salzman C. Medication compliance in the elderly. J Clin Psychiatry. 1995;56(Suppl 1):18–22.PubMed Salzman C. Medication compliance in the elderly. J Clin Psychiatry. 1995;56(Suppl 1):18–22.PubMed
34.
Zurück zum Zitat Giagounidis A, di Leto PS, Ille S, Fenaux P. A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS. Ann Hematol. 2011;90:667–73.PubMedCrossRef Giagounidis A, di Leto PS, Ille S, Fenaux P. A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS. Ann Hematol. 2011;90:667–73.PubMedCrossRef
35.
Zurück zum Zitat Rofail D, Abetz L, Viala M, et al. Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrument. Value Health. 2009;12:109–17.PubMedCrossRef Rofail D, Abetz L, Viala M, et al. Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrument. Value Health. 2009;12:109–17.PubMedCrossRef
36.
Zurück zum Zitat Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy. Oncologist. 2009;14:489–96.PubMedCrossRef Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy. Oncologist. 2009;14:489–96.PubMedCrossRef
37.
Zurück zum Zitat Cappellini MD, Porter JB, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias. Haematologica. 2010;95:557–66.PubMedCrossRef Cappellini MD, Porter JB, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias. Haematologica. 2010;95:557–66.PubMedCrossRef
38.
Zurück zum Zitat Gattermann N, Finelli C, Della Porta M, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res. 2010;34:1143–50.PubMedCrossRef Gattermann N, Finelli C, Della Porta M, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res. 2010;34:1143–50.PubMedCrossRef
39.
Zurück zum Zitat Amico KR, Toro-Alfonso J, Fisher JD. An empirical test of the information, motivation and behavioral skills model of antiretroviral therapy adherence. AIDS Care. 2005;17:661–73.PubMedCrossRef Amico KR, Toro-Alfonso J, Fisher JD. An empirical test of the information, motivation and behavioral skills model of antiretroviral therapy adherence. AIDS Care. 2005;17:661–73.PubMedCrossRef
40.
Zurück zum Zitat Johnson MJ. The Medication Adherence Model: a guide for assessing medication taking. Res Theory Nurs Pract. 2002;16:179–92.PubMedCrossRef Johnson MJ. The Medication Adherence Model: a guide for assessing medication taking. Res Theory Nurs Pract. 2002;16:179–92.PubMedCrossRef
Metadaten
Titel
The challenges of adherence and persistence with iron chelation therapy
verfasst von
John B. Porter
Michael Evangeli
Amal El-Beshlawy
Publikationsdatum
01.11.2011
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 5/2011
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-011-0927-3

Weitere Artikel der Ausgabe 5/2011

International Journal of Hematology 5/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.